MD 1105
Alternative Names: MD1105Latest Information Update: 28 Apr 2021
At a glance
- Originator MedDay Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in France
- 10 Mar 2017 Preclinical trials in Alzheimer's disease in France (unspecified route) (MedDay Pharmaceuticals pipeline, March 2017) before March 2017